Prevalence and features of eosinophilic gastrointestinal disorders using the large real-world TriNetX database
Abstract
Background: There are substantial questions concerning the epidemiology and demographics of eosinophilic gastrointestinal disorders (EGID). We queried TriNetX, a large electronic medical record database, to assess EGID demographics.
Objectives: Our objective for this study was to characterize the prevalence, demographic features, disease overlap, and treatment patterns of patients with EGID using a large multicenter electronic health record database.
Methods: TriNetX, a deidentified patient database derived from 92 health care organizations and a total population of 129,260,452 patients, was queried for EGID. Cases were identified by ICD codes (eosinophilic esophagitis [EoE] K20, eosinophilic gastritis/enteritis [EoG/EoN] K52.81, eosinophilic colitis [EoC] K52.82) and endoscopy occurrence. Demographic and clinical characteristics were analyzed.
Results: We identified 77,726 EoE, 6,554 EoG/EoN, and 2,898 EoC cases. Prevalence was approximately 1:1,673, 1:19,842, and 1:44,873, respectively. Multiple EGID occurred in 5% of all patients but in 47% of those with EoG/EoN. EGID was most common in non-Hispanic White individuals (79%). Male predominance was observed in EoE (59%) but not EoG/EoN (46%) or EoC (45%). Mean patient ages at query were 39, 31, and 40 years for EoE, EoG/EoN, and EoC, respectively (P < .0001). The most prescribed medications were proton pump inhibitors for EoE, antiemetics and corticosteroids for EoG/EoN, and corticosteroids for EoC.
Conclusions: We…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 260,452 participants or records.
Read the paper
Related studies
- Patient-Centered Pharmaceutical Design to Improve Acceptability of Medicines: Similarities and Differences in Paediatric and Geriatric Populations
- Evidence-based clinical practice guidelines for irritable bowel syndrome 2020
- Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial
- Gastrointestinal manifestations in COVID-19
- COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist
- Persistent gut barrier damage and commensal bacterial influx following eradication of Giardia infection in mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.